UiPath (NYSE:PATH) PT Raised to $25.00

UiPath (NYSE:PATH) had its price objective hoisted by Morgan Stanley from $17.00 to $25.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the healthcare company’s stock. Morgan Stanley’s price target points to a potential upside of 8.39% from the stock’s current price.

A number of other equities research analysts have also recently commented on PATH. JPMorgan Chase & Co. upgraded shares of UiPath from a “neutral” rating to an “overweight” rating and increased their target price for the company from $22.00 to $28.00 in a research report on Thursday. TD Cowen lifted their target price on shares of UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. William Blair started coverage on shares of UiPath in a research note on Tuesday, January 2nd. They set an “outperform” rating on the stock. Wells Fargo & Company boosted their price target on shares of UiPath from $18.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, December 1st. Finally, Mizuho boosted their price target on shares of UiPath from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Friday, December 1st. Nine investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $27.13.

UiPath Stock Up 1.4 %

Shares of UiPath stock traded up $0.32 on Thursday, reaching $23.07. 9,842,354 shares of the stock were exchanged, compared to its average volume of 10,074,664. UiPath has a twelve month low of $12.38 and a twelve month high of $27.87. The firm has a market capitalization of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The business has a 50 day moving average price of $23.52 and a two-hundred day moving average price of $20.70.

Insider Activity at UiPath

In other news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the completion of the transaction, the director now owns 429,418 shares of the company’s stock, valued at approximately $9,928,144.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the sale, the chief financial officer now owns 103,505 shares in the company, valued at approximately $2,325,757.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Rich Wong sold 200,000 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The disclosure for this sale can be found here. Insiders sold a total of 411,000 shares of company stock worth $9,418,670 in the last ninety days. 31.03% of the stock is currently owned by insiders.

Hedge Funds Weigh In On UiPath

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC bought a new stake in shares of UiPath during the fourth quarter valued at about $25,000. HighMark Wealth Management LLC bought a new position in shares of UiPath during the fourth quarter valued at about $27,000. Tyler Stone Wealth Management bought a new position in shares of UiPath during the second quarter valued at about $28,000. Cypress Capital Management LLC WY bought a new position in shares of UiPath during the fourth quarter valued at about $29,000. Finally, Fifth Third Bancorp increased its position in shares of UiPath by 2,005.3% during the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock valued at $34,000 after buying an additional 1,905 shares during the period. 59.04% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.